Contents

Preface to the Second Edition *xv*

1 Solid State and Polymorphism of the Drug Substance in the Context of Quality by Design and ICH Guidelines Q8–Q12 *1*
Markus von Raumer and Rolf Hilfiker
1.1 Introduction *1*
1.2 A Short Introduction to Polymorphism and Solid-State Development *1*
1.3 A Short Introduction to Quality by Design (QbD) *3*
1.4 The Solid State in the Context of Pharmaceutical Development *7*
1.4.1 Typical Drug Discovery and Development *7*
1.4.2 The Solid State at the Interface of Drug Substance and Drug Product *10*
1.4.3 Biopharmaceutics and Bioavailability of Solids *11*
1.4.4 Pharmaceutical Quality Assessment *14*
1.5 Solid-State Development at Various Stages of the Pharmaceutical Development Process *15*
1.5.1 The Solid State in the Discovery Phase *16*
1.5.2 Salt and Co-crystal Screening and Selection *16*
1.5.3 Polymorph Screening, Polymorph Landscape, and Polymorph Transformations *17*
1.5.4 Crystallization and Downstream Processes *20*
1.5.5 Formulation *21*
1.5.6 Analytical Methods for Characterization and Physical Purity Determination *22*
1.6 Conclusions *23*
References *23*

2 Alternative Solid Forms: Salts *31*
P.H. Stahl, Bertrand Sutter, Arnaud Grandeury, and Michael Mutz
2.1 Introduction *31*
2.2 Salt Formation and Polymorphism in Pharmaceutical Development *31*
2.3 Target Properties of Active Substances for Drug Products *33*
2.3.1 Injectables *34*

2.3.2 Solid Dosage Forms *35*
2.3.3 Dosage Forms for Other Routes of Application *36*
2.3.3.1 Inhalation *36*
2.3.3.2 Topical Products and Transdermal Route *36*
2.4 The Basics of Salt Formation *37*
2.4.1 Dissociation Constant *37*
2.4.2 Ionization and pH *39*
2.4.3 Solubility *40*
2.4.4 Disproportionation *43*
2.5 Approaches to Salt Preparation and Characterization *45*
2.5.1 Initial Data *45*
2.5.2 Selection of Salt Formers *45*
2.5.3 Salt Preparation Procedures *46*
2.6 Selection Strategies *49*
2.6.1 Points to be Considered *49*
2.6.2 Final Decision *51*
2.6.3 Salt Form and Life Cycle Management of Drug Products *52*
2.7 Case Reports *53*
2.7.1 Overview of Salt Forms Selected *53*
2.7.2 The Salt Selection Process *53*
2.7.3 Case 1: NVP-BS001 *53*
2.7.4 Case 2: NVP-BS002 *54*
2.8 Discussion and Decision *56*
References *56*

3 Alternative Solid Forms: Co-crystals *61*
Johan Wouters, Dario Braga, Fabrizia Grepioni, Luc Aerts, and Luc Quéré
3.1 Introduction *61*
3.2 Types of Pharmaceutical Co-crystals *62*
3.2.1 Salts *vs* Co-crystals *62*
3.2.2 Ionic Co-crystals of API *63*
3.2.3 Polymorphism and Co-crystals *65*
3.3 Relevant Pharmaceutical Co-crystal Properties *65*
3.3.1 Solubility *66*
3.3.2 Dissolution Rate *67*
3.3.3 Bioavailability *69*
3.3.4 Melting Point *69*
3.3.5 Stability *70*
3.3.6 Challenges and Undesired Effect of Co-crystallization *71*
3.4 Analytical Tools to Characterize Co-crystals *73*
3.4.1 Microscopy *74*
3.4.2 X-Ray Diffraction *75*
3.4.3 Thermal Analysis *77*
3.4.4 Vibrational Spectroscopy *77*
3.4.5 Solid-State NMR *78*
3.5 Patent Literature Review *79*
3.6 Current View on Regulatory Aspects of PCCs *83*

3.6.1 Rules Governing Manufacturing (API GMP) *84*
3.6.2 ICH Tripartite Guidelines on Specifications for New Drug Substances and New Drug Products *85*
3.7 Conclusions *85*
Acknowledgment *85*
References *86*

4 Thermodynamics of Polymorphs and Solvates *91*
Gerard Coquerel
4.1 Basic Notions *91*
4.1.1 Chemical Purity *92*
4.1.2 Isotopic Purity *92*
4.1.3 Structural Purity *92*
4.1.4 Stability of the Component *93*
4.1.5 Polymorphism, Desmotropy, Allotropism, and Chirality *93*
4.1.6 Gibbs Phase Rule *93*
4.1.7 Unary System or Unary Section Without Polymorphism *94*
4.2 Unary System or Unary Section with Polymorphism *95*
4.2.1 Access to Polymorphs *97*
4.2.2 Mechanisms of Polymorphic Transition *98*
4.3 Polymorphism in Binary Systems *98*
4.3.1 No Mixed Crystals *98*
4.3.1.1 Polymorphism of One Component Only *98*
4.3.1.2 Three Enantiotropic Polymorphs *100*
4.3.1.3 Two Enantiotropic Polymorphs and One Form with Monotropic Character *100*
4.3.1.4 One Stable Polymorph and Two Forms with a Monotropic Character *100*
4.3.1.5 Polymorphism of a Stoichiometric Compound *100*
4.3.2 Polymorphism and Mixed Crystals *102*
4.3.2.1 Polymorphism of One Component Only *102*
4.3.2.2 Two Stable Polymorphic Forms for One Component with Full Miscibility in the Solid State (at a Certain Temperature) *105*
4.3.2.3 Two Stable Polymorphic Forms for One Component with Limited Miscibility in the Solid State *108*
4.3.2.4 One Stable Form and One Metastable Form (Monotropic Character) with Full Miscibility for the Metastable Form *109*
4.3.2.5 One Stable Form and One Metastable Form (Monotropic Character) with Full Miscibility for the Metastable Form *111*
4.3.2.6 Two Isostructural Monotropic Forms When Mixed Could Lead to an Enantiotropy *112*
4.3.2.7 Limitations of the Concept of Polymorphism and Other Solid(s) to Solid(s) Transitions *112*
4.3.3 Solvates *114*
4.3.3.1 Differentiation Between Stoichiometric and Nonstoichiometric Solvates *116*
4.3.3.2 Hygroscopicity, Deliquescence, and Efflorescence *117*

4.4 Ternary Systems *119*
4.4.1 Chiral Discrimination via the Formation of Solvates *121*
4.5 Temperature of Desolvation – T_g and New Polymorphs Only Accessible Through a Smooth Solvation – Desolvation Process *123*
4.6 Concluding Remarks *126*
Acknowledgments *127*
References *127*

5 Toward Computational Polymorph Prediction *133*
Sarah L. Price and Louise S. Price
5.1 Could a Computer Predict Polymorphs for the Pharmaceutical Industry? *133*
5.1.1 Predicting the Thermodynamically Most Stable Structure from the Chemical Diagram *134*
5.1.2 Using Crystal Structure Prediction Studies as a Complement to Solid-form Screening *134*
5.2 Methods of Calculating the Relative Energies of Crystals *136*
5.2.1 Lattice Energy *136*
5.2.2 Free Energy *139*
5.3 Searching for Possible Crystal Structures *140*
5.4 Comparing Crystal Structures *141*
5.5 Calculation of Properties from Crystal Structures *142*
5.5.1 Spectroscopic – PXRD, IR, ss-NMR *142*
5.5.2 Other Properties: Solubilities, Morphologies, and Mechanical Properties *143*
5.6 Crystal Energy Landscapes *145*
5.6.1 Interpretation of Crystal Energy Landscapes *145*
5.6.2 Example of Tazofelone *146*
5.7 Potential Uses of Crystal Energy Landscapes in the Pharmaceutical Industry *148*
5.7.1 Confirming the Most Stable Structure is Known *148*
5.7.2 Suggesting Experiments to Find New Polymorphs *148*
5.7.3 Aiding Structural Characterization from Limited Experimental Data *149*
5.7.4 Anticipating Disorder *149*
5.7.5 Understanding Crystallization Behaviors *149*
5.8 Outlook *150*
References *151*

6 Hygroscopicity and Hydrates in Pharmaceutical Solids *159*
Susan M. Reutzel-Edens, Doris E. Braun, and Ann W. Newman
6.1 Introduction *159*
6.2 Thermodynamics of Water–Solid Interactions *160*
6.3 Hygroscopicity *161*
6.3.1 Moisture Sorption Analysis *162*
6.3.2 Hygroscopic Behaviors in Pharmaceutical Solids *166*
6.4 Hydrates *168*

6.4.1 Statistics of Hydrate Appearance *168*
6.4.2 Hydrate Crystallization *170*
6.4.3 Structures and Properties *174*
6.5 Significance and Strategies for Developing Hydrate-Forming Systems *180*
6.6 Conclusions *184*
References *184*

7 The Amorphous State *189*
Marc Descamps, Emeline Dudognon, and Jean-François Willart
7.1 Introduction *189*
7.2 Amorphous/Crystalline Solids: Terminology and Brief Confrontation *190*
7.2.1 Structural Aspects *190*
7.2.2 The Concept(s) of Solid State: Rheological Aspect *191*
7.2.3 Crystal Melting vs Glass Softening *192*
7.3 Order and Disorder: Structural Identification of Amorphous and Crystal States *193*
7.3.1 How Disordered can a Crystal Be? *193*
7.3.1.1 Crystallinity: Definition, Experimental Identification *193*
7.3.1.2 Small or Disordered "Perfect" Crystals *193*
7.3.2 Structure of Glassy and Amorphous Compounds. How Ordered can They be? *194*
7.4 Amorphous Stability, Crystallization Avoidance, and Glass Formation *198*
7.4.1 Metastability, Driving Force for Crystallization *198*
7.4.2 Kinetics of Crystallization via Nucleation and Growth *198*
7.4.3 Conventional Glass Formation *201*
7.4.4 Notes on the Assessment and Prediction of Amorphous Stability *202*
7.4.4.1 Role of Molecular Mobility *202*
7.4.4.2 Role of the Liquid/Crystal Interface Energy and Structural Similarity *202*
7.4.4.3 Role of Polymorphism *203*
7.4.4.4 Heterogeneous Nucleation *204*
7.4.4.5 Confinement and Size Effect *204*
7.4.4.6 To Summarize *205*
7.5 The Glass Transition *205*
7.5.1 Calorimetric Signature at T_g *205*
7.5.2 Calorimetric Glass Transition: Signification *206*
7.5.3 The C_p Jump at T_g: *Fragile* and *Strong* Glass Formers *207*
7.5.4 Glass Transition and Entropy Crisis: The Kauzmann Paradox *207*
7.5.5 Glassy Amorphous State: Instability and Energy Landscape *208*
7.6 Molecular Mobility for $T > T_g$ *210*
7.6.1 Mobility of Fragile and Strong Glass Formers *210*
7.6.2 Link Between Mobility and Entropy *212*
7.6.3 Cooperative Rearrangement Regions (CRR) *213*

7.6.4 Dynamic Heterogeneity: Non-exponentiality of the Relaxation *213*
7.7 Molecular Mobility and Instability for $T < T_g$ *214*
7.7.1 The Aging Phenomenon *214*
7.7.2 Approximate Assessment of Stability *215*
7.7.2.1 Fictive Temperature *216*
7.7.3 Nonlinearity *217*
7.7.4 Secondary Relaxations *218*
7.8 Multicomponent Amorphous Systems: Solubility and Stability Issues *220*
7.8.1 Solubility: Comparison of Crystalline and Amorphous States *220*
7.8.2 T_g of Amorphous Multicomponent System *223*
7.8.3 Improved Dissolution Properties *224*
7.8.4 Mixing and Stabilization *224*
7.9 Methods of Amorphization *226*
7.10 Influence of Processing on Properties *230*
7.11 Concluding Remarks *231*
References *232*

8 Approaches to Solid-Form Screening *241*
Rolf Hilfiker, Fritz Blatter, Martin Szelagiewicz, and Markus von Raumer
8.1 Screening for Salts and Co-crystals *242*
8.1.1 Example of a Co-crystal Screen *243*
8.2 Polymorphs, Hydrates, and Solvates *245*
8.3 Screening for Polymorphs, Hydrates, and Solvates *245*
8.3.1 Crystallization Methods *248*
8.3.2 Choice of Solvent *250*
8.3.3 Types of Polymorph Screens *251*
8.3.4 Characterization and Selection *253*
8.4 Conclusion *255*
References *256*

9 Nucleation *261*
Marco Mazzotti, Thomas Vetter, David R. Ochsenbein, Giovanni M. Maggioni, and Christian Lindenberg
9.1 Introduction *261*
9.2 Homogeneous Nucleation *262*
9.2.1 Classical Nucleation Theory *264*
9.2.2 Two-Step Nucleation Theory *266*
9.3 Heterogeneous and Secondary Nucleation *268*
9.3.1 Heterogeneous Nucleation *268*
9.3.2 Secondary Nucleation *268*
9.4 Characterization of Nucleation *270*
9.4.1 Deterministic Nucleation Rates *270*
9.4.2 Stochastic Nucleation Rates *272*
9.5 Order of Polymorph Appearance – Ostwald's Rule of Stages *275*
9.6 To Seed or Not to Seed? *277*
9.6.1 Process Control *277*

9.6.2 Polymorphism Control *279*
9.6.3 Impurity Control *279*
References *280*

10 Crystallization Process Modeling *285*
Marco Mazzotti, Thomas Vetter, and David R. Ochsenbein
10.1 Introduction *285*
10.1.1 Population Balance Equations *286*
10.1.2 Notes Regarding Population Balance Models *288*
10.1.2.1 Energy Balances and Fluid Dynamics *288*
10.1.2.2 Solution of Population Balance Equations *288*
10.1.2.3 Applications *289*
10.2 System Characterization and Optimization *289*
10.2.1 Crystal Growth *290*
10.2.2 Polymorph Transformation *291*
10.2.3 Agglomeration *292*
10.2.4 Optimization *295*
10.3 Multidimensional Population Balance Modeling *297*
10.4 Conclusion *300*
References *301*

11 Crystallization Process Scale-Up, a Quality by Design (QbD) Perspective *305*
Andrei A. Zlota
11.1 Introduction *305*
11.2 API Critical Quality Attributes (CQAs) *306*
11.3 Statistical Design of Experiments (DoE) for Crystallization Process Development *306*
11.3.1 Example: DoE Methodology to Develop a Robust Crystallization Process, a Case of an API Developed as a Polymorphic Mixture *307*
11.4 Process Analytical Technology (PAT) for Polymorph Control *314*
11.5 Mixing and Scale-Up Investigations *316*
11.5.1 Scale-Up Factors, Mass Transfer *316*
11.5.2 Scale-Up Factors in Crystallization Processes *318*
11.5.3 Mixing Impact on the Metastable Zone Width (MSZW) *324*
11.5.4 Disappearing Polymorphs During Scale-Up *324*
11.5.5 Polymorph Control Methods Based on Mixing *324*
11.5.6 Heat Transfer *325*
11.6 Conclusions and Outlook *326*
References *326*

12 Processing-Induced Phase Transformations and Their Implications on Pharmaceutical Product Quality *329*
Seema Thakral, Ramprakash Govindarajan, and Raj Suryanarayanan
12.1 Introduction *329*
12.2 Pharmaceutical Processes Causing Unintended Phase Transformations *333*

12.2.1 Milling *333*
12.2.2 Granulation and Drying – Hydration and Dehydration *336*
12.2.2.1 Hydrate Formation *337*
12.2.2.2 Dehydration *338*
12.2.3 Compression *342*
12.2.4 Freezing Aqueous Solutions *345*
12.3 Pharmaceutical Processes Causing Intended Phase Transformations – Obtaining the Desired Physical Form *346*
12.3.1 Spray-drying *346*
12.3.2 Freeze-drying *347*
12.3.3 Hot Melt Extrusion *349*
12.3.4 Co-milling/Co-grinding *350*
12.4 Phase Transformations During Pharmaceutical Processing – Implications *351*
12.4.1 Creating Disorder – Amorphization *352*
12.4.1.1 Altered Particulate and Bulk Properties *352*
12.4.1.2 Implications on Chemical Stability *353*
12.4.1.3 Solubility and Bioavailability Enhancement *356*
12.4.2 Formation of Crystalline Mesophases *357*
12.4.3 Restoring Order – Promoting In-process Recrystallization *358*
12.4.3.1 In Frozen Solutions *358*
12.4.3.2 Miscellaneous Processes *359*
12.4.4 Amorphization and Crystallization During Freeze-drying *359*
12.4.5 Changes in Chemical Composition *364*
12.4.5.1 Hydrate Formation and Dehydration *364*
12.4.5.2 "Co-amorphization" *365*
12.4.5.3 Co-crystal Formation *366*
12.4.5.4 Salt Formation and Disproportionation *366*
12.5 Conclusion *368*
References *369*

13 Surface and Mechanical Properties of Molecular Crystals *381*
M. Teresa Carvajal and Xiang Kou
13.1 Introduction *381*
13.2 Surface Properties *382*
13.2.1 Structure–Property–Response/Performance *385*
13.2.2 Case Study #1 – Milling-Induced Agglomeration *386*
13.2.3 Case Study #2 – Batch-to-batch Variability *390*
13.2.4 Case Study #3 – Hydration–Dehydration *393*
13.2.5 Case Study #4 – Surface Interactions and Bulk Properties *395*
13.3 Remarks *399*
13.4 Impact of Polymorphism on Powder Flow *401*
13.5 Impact of Polymorphism on Mechanical Properties of Molecular Crystals *402*
13.6 Impact of Polymorphism on Size Reduction by Milling *405*
13.7 Impact of Polymorphism on Powder Compaction Properties *406*
References *409*

14 Analytical Tools to Characterize Solid Forms *415*
Rolf Hilfiker, Susan M. De Paul, and Timo Rager
14.1 Crystal Structure *415*
14.1.1 X-ray Diffraction (XRD) *416*
14.1.2 Vibrational Spectroscopy (Raman, mid-IR, NIR, and THz) *417*
14.1.3 Solid-State NMR (ssNMR) Spectroscopy *424*
14.2 Thermodynamic Properties *431*
14.2.1 Differential Scanning Calorimetry (DSC) *431*
14.2.2 Isothermal Microcalorimetry (IMC) *436*
14.2.3 Solution Calorimetry (SolCal) *438*
14.3 Composition Solvate/Hydrate Stoichiometry *439*
14.3.1 Thermogravimetry (TGA, TG–FTIR, and TG–MS) *439*
14.3.2 Dynamic Vapor Sorption (DVS) *440*
14.4 Conclusion *443*
References *443*

15 Industry Case Studies *447*
Ralph Diodone, Pirmin C. Hidber, Michael Kammerer, Roland Meier, Urs Schwitter, and Jürgen Thun
15.1 Introduction *447*
15.1.1 Screening and Selection of Solid Forms *447*
15.1.2 Control Strategy for the Solid Form *448*
15.2 Case Study #1: Holistic Control Strategy for Solid Form *449*
15.2.1 Solid-Form Control for Drug Substance *449*
15.2.2 Solid-Form Control for Drug Product *450*
15.3 Case Study #2: Solid-Form Control of API for Low-Dose Drug *451*
15.4 Case Study #3: Development of Crystallization Process and Unexpected Influence of Impurity *453*
15.5 Case Study #4: Hydrate/Anhydrate Dilemma *456*
15.6 Case Study #5: *Quality by Design* by Selecting a Cocrystal *458*
15.7 Case Study #6: Dealing with the Consecutive Appearance of New Polymorphs *460*
15.8 Case Study #7: Amorphous API: Issues to be Considered in Drug Development *464*
15.9 Case Study #8: Computational Prediction of Unknown Polymorphs and Experimental Confirmation *466*
References *467*

16 Pharmaceutical Crystal Forms and Crystal-Form Patents: Novelty and Obviousness *469*
Joel Bernstein and Jill MacAlpine
16.1 Introduction *469*
16.2 Novelty and Obviousness *470*
16.3 The Scientific Perspective *471*
16.3.1 Novelty from a Scientific Perspective *471*
16.3.2 Obviousness from a Scientific Perspective *472*
16.4 The Role of Serendipity in Crystal Forms *475*

16.5 History of Crystal-Form Patents *477*
16.6 Typical *Ex Post Facto* Arguments on Obviousness *478*
16.7 Conclusion *482*
Acknowledgment *482*
References *482*

Index *485*